Who Makes Benlysta?

As a revolutionary treatment option for those suffering from systemic lupus erythematosus (SLE), Benlysta has been heralded as a major breakthrough in the field of autoimmune diseases. But who makes Benlysta? In this article, we’ll explore the company behind this revolutionary drug, and how Benlysta has revolutionized the management of SLE.

Benlysta is a prescription medicine manufactured by Human Genome Sciences, Inc., a subsidiary of GlaxoSmithKline plc. Benlysta is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for lupus in over 50 years. It is available in two forms: an injection and a subcutaneous formulation.

Who Makes Benlysta?

Benlysta (belimumab) is a prescription medication used to treat systemic lupus erythematosus (SLE). It is a human monoclonal antibody, manufactured and marketed by Human Genome Sciences (HGS) and GlaxoSmithKline (GSK). Benlysta was first approved by the U.S. Food and Drug Administration (FDA) in March 2011 and is the first FDA-approved treatment specifically for lupus in over 50 years.

Who Makes Benlysta

Human Genome Sciences (HGS)

Human Genome Sciences is a biopharmaceutical company based in Rockville, Maryland. Founded in 1992, the company focuses on research and development of innovative therapies for serious diseases. It develops and manufactures biopharmaceuticals, including Benlysta and other human monoclonal antibodies.

GlaxoSmithKline (GSK)

GlaxoSmithKline is a multinational pharmaceutical company based in the UK. Founded in 2000, the company produces a wide range of medicines, vaccines, and consumer healthcare products. GSK is the co-developer and marketing partner of Benlysta, and is responsible for commercializing and distributing the drug in more than 85 countries.

Manufacturing Benlysta

Benlysta is manufactured in a state-of-the-art facility in Cambridge, MA. The manufacturing process is complex, involving multiple steps and quality checks. The process includes fermentation, purification, and formulation of the antibody into a finished product. The manufacturing process is strictly regulated by the FDA and the European Medicines Agency (EMA) to ensure the quality and safety of the drug.

Related FAQ

Who Makes Benlysta?

Answer: Benlysta (belimumab) is a prescription medication used to treat adult and pediatric patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. Benlysta is made by Human Genome Sciences, Inc., a biopharmaceutical company headquartered in Rockville, Maryland.

What is Benlysta Used to Treat?

Answer: Benlysta (belimumab) is used to treat adult and pediatric patients with active, autoantibody-positive, systemic lupus erythematosus (SLE). SLE is an autoimmune disease, meaning the body’s immune system mistakenly attacks healthy tissue. Benlysta is used in combination with standard therapy and is not a substitute for other treatments.

How Does Benlysta Work?

Answer: Benlysta works by targeting a specific protein in the body known as B lymphocyte stimulator (BLyS). BLyS is a protein that helps immune cells to survive and proliferate, and is overactive in people with SLE. By targeting and inactivating BLyS, Benlysta helps reduce the activity of the immune system and helps to reduce the symptoms of SLE.

How is Benlysta Administered?

Answer: Benlysta is administered via intravenous infusion. The medication is given through a needle inserted into the vein. The infusion usually takes about an hour, and the patient is monitored during the infusion for any adverse reactions.

What are the Side Effects of Benlysta?

Answer: The most common side effects of Benlysta include nausea, upper respiratory tract infection, headache, and fatigue. Other serious side effects may include allergic reactions, anemia, and infusion reactions.

Is Benlysta Covered by Insurance?

Answer: Yes, Benlysta is typically covered by most insurance plans. However, coverage may vary depending on the specific plan and the patient’s individual circumstances. Patients should check with their insurance provider for details about their coverage.

Benlysta is a revolutionary new medication that is changing the way many people with lupus manage the symptoms of their condition and lead healthier and fuller lives. Developed by Human Genome Sciences and GlaxoSmithKline, Benlysta was created to help those suffering from lupus gain some control over their symptoms and to improve their quality of life. With its unique and innovative approach to treating lupus, Benlysta is a life-changing medication for many and a testament to the hard work and dedication of Human Genome Sciences and GlaxoSmithKline.

Leave a Reply

Your email address will not be published. Required fields are marked *